BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 35571561)

  • 1. Development of a Transcription Factor-Based Prognostic Model for Predicting the Immune Status and Outcome in Pancreatic Adenocarcinoma.
    Zhang X; Li L; Liu P; Tian Y; Gong P
    J Immunol Res; 2022; 2022():4946020. PubMed ID: 35571561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and Validation of an Inflammatory Response-Related Gene Signature for Predicting the Prognosis of Pancreatic Adenocarcinoma.
    Deng ZL; Zhou DZ; Cao SJ; Li Q; Zhang JF; Xie H
    Inflammation; 2022 Aug; 45(4):1732-1751. PubMed ID: 35322324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a Prognostic Model Based on Pyroptosis-Related Genes in Pancreatic Adenocarcinoma.
    Su K; Peng Y; Yu H
    Dis Markers; 2022; 2022():9141117. PubMed ID: 35677632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a Four Cancer Stem Cell-Related Gene Signature and Establishment of a Prognostic Nomogram Predicting Overall Survival of Pancreatic Adenocarcinoma.
    Li S; Chen R; Luo W; Lin J; Chen Y; Wang Z; Lin W; Li B; Wang J; Yang J
    Comb Chem High Throughput Screen; 2022; 25(12):2070-2081. PubMed ID: 35048799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High expression of LAMA3/AC245041.2 gene pair associated with KRAS mutation and poor survival in pancreatic adenocarcinoma: a comprehensive TCGA analysis.
    Tian C; Li X; Ge C
    Mol Med; 2021 Jun; 27(1):62. PubMed ID: 34134622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. System analysis based on the pyroptosis-related genes identifies GSDMC as a novel therapy target for pancreatic adenocarcinoma.
    Yan C; Niu Y; Li F; Zhao W; Ma L
    J Transl Med; 2022 Oct; 20(1):455. PubMed ID: 36199146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of an autophagy-related gene signature for predicting prognosis and immune activity in pancreatic adenocarcinoma.
    Deng J; Zhang Q; Lv L; Ma P; Zhang Y; Zhao N; Zhang Y
    Sci Rep; 2022 Apr; 12(1):7006. PubMed ID: 35488119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identify potential prognostic indicators and tumor-infiltrating immune cells in pancreatic adenocarcinoma.
    Shi T; Gao G
    Biosci Rep; 2022 Feb; 42(2):. PubMed ID: 35083488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of an Autophagy-Related Pair Signature for Predicting Prognoses and Immune Activity in Pancreatic Adenocarcinoma.
    Zhang Q; Lv L; Ma P; Zhang Y; Deng J; Zhang Y
    Front Immunol; 2021; 12():743938. PubMed ID: 34956177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Value of E2F Transcription Factor Expression in Pancreatic Adenocarcinoma.
    Luo L; Zhang G; Wu T; Wu G
    Med Sci Monit; 2021 Nov; 27():e933443. PubMed ID: 34799547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel immune checkpoint score system for prognostic evaluation in pancreatic adenocarcinoma.
    Chen Y; Lin X; Zou X; Qian Y; Liu Y; Wang R; Wang X; Yu X; Liu C; Cheng H
    BMC Gastroenterol; 2023 Apr; 23(1):113. PubMed ID: 37024802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and validation of a hypoxia-stemness-based prognostic signature in pancreatic adenocarcinoma.
    Tian X; Zheng J; Mou W; Lu G; Chen S; Du J; Zheng Y; Chen S; Shen B; Li J; Wang N
    Front Pharmacol; 2022; 13():939542. PubMed ID: 35935823
    [No Abstract]   [Full Text] [Related]  

  • 13. Development and validation of a novel glycolysis-related risk signature for predicting survival in pancreatic adenocarcinoma.
    Li A; Hou S; Chen J; Jiang Y
    Clin Chim Acta; 2021 Jul; 518():156-161. PubMed ID: 33775699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and validation of cuproptosis-related lncRNAs associated with pancreatic cancer immune microenvironment based on single-cell.
    Sun Y; Yao L; Man C; Gao Z; He R; Fan Y
    Front Immunol; 2023; 14():1220760. PubMed ID: 37822927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between a 7-mRNA signature of the pancreatic adenocarcinoma microenvironment and patient prognosis (a STROBE-compliant article).
    He QL; Jiang HX; Zhang XL; Qin SY
    Medicine (Baltimore); 2020 Jul; 99(29):e21287. PubMed ID: 32702921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Construction and Validation of an Immune-Based Prognostic Model for Pancreatic Adenocarcinoma Based on Public Databases.
    Mao M; Ling H; Lin Y; Chen Y; Xu B; Zheng R
    Front Genet; 2021; 12():702102. PubMed ID: 34335699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Construction of a novel signature based on immune-related lncRNA to identify high and low risk pancreatic adenocarcinoma patients.
    Li N; Chen J; Yu W; Huang X
    BMC Gastroenterol; 2023 Sep; 23(1):312. PubMed ID: 37710166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pancreatic adenocarcinoma associated immune-gene signature as a novo risk factor for clinical prognosis prediction in hepatocellular carcinoma.
    Dai L; Mugaanyi J; Cai X; Lu C; Lu C
    Sci Rep; 2022 Jul; 12(1):11944. PubMed ID: 35831362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring the significance of novel immune-related gene signatures in the prognosis and immune features of pancreatic adenocarcinoma.
    Chen B; Hu C; Jiang L; Xiang Z; Zuo Z; Lin Y; Liu C
    Int Immunopharmacol; 2021 Mar; 92():107359. PubMed ID: 33465729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dissection of pyroptosis-related prognostic signature and CASP6-mediated regulation in pancreatic adenocarcinoma: new sights to clinical decision-making.
    Zhu J; Shi Y; Lan S; Wang J; Jiang F; Tang C; Cai Y; Pan Z; Jian H; Fang H; Zhang Y; Zhong F
    Apoptosis; 2023 Jun; 28(5-6):769-782. PubMed ID: 36882663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.